Healthcare
Collegium Pharmaceutical Inc(COLL)
Live Price
Offline$34.64
+0.87% today
1Y Change
+17.08%
Window
Jun 30, 2025 โ Jun 23, 2026
- Market Cap
- $1.14B
- Revenue Growth
- +23.6%
- EPS Growth
- -7.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 30, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Collegium Pharmaceutical Inc (COLL) is a Healthcare stock with a market cap of $1.14B and listed on NASDAQ. The stock last traded around $34.64 and up 17.1% across the available one-year price window (Jun 30, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +23.6%, EPS growth of -7.5%, a dividend yield of 0.0%. What stands out right now is revenue +23.6%, EPS -7.5%, free cash flow +61.1% with operating margin 23.0% and ROIC 9.8%. Valuation is more restrained than many high-expectation growth names at P/E 17.8 and price/sales 1.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines COLL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+23.6% vs +7.6% peer median
Operating Margin
Above sector median
+23.0% vs +19.4% peer median
P/E
Below sector median
17.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +23.6% and EPS is at -7.5%, with operating margin around 23.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.0% | -1.2% | -0.5% |
2026 Feb 26, 2026 | -4.7% | -5.8% | -15.7% | -24.4% |
2025 Nov 6, 2025 | +21.0% | +4.0% | +14.1% | +17.8% |
Benchmark Edge
COLL vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
COLL trails SPY
COLL is 1.65 pts behind over the shared 1Y window.
COLL had 29.71 pts deeper max drawdown than SPY.
COLL beat SPY in 1 of 2 calendar years shown and trailed in 1.
COLL
+17.08%
Normalized return
SPY
+18.73%
S&P 500
Excess Return
-1.65 pts
Relative to SPY
COLL Max Drawdown
-38.84%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COLL and SPY.
| Year | COLL | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -23.96% | +6.71% | -30.67 pts | SPY |
| 2025 | +59.38% | +11.19% | +48.19 pts | COLL |
Company Overview
Collegium Pharmaceutical Inc
NASDAQ
Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone. Collegium also offers Nucynta products in extended-release and immediate-release formulations, along with Symproic for opioid-induced constipation. The company employs proprietary DETERx platform technology designed to maintain safety profiles while deterring abuse through various manipulation methods. Headquartered in Stoughton, Massachusetts, and founded in 2002, Collegium serves healthcare providers and patients across the United States, positioning itself as a leader in responsible pain management and ADHD treatment.
- Leadership
- Mr. Vikram Karnani
- Employees
- 357
- Street Address
- 100 Technology Center Drive, Suite 300
- Mailing
- Stoughton, MA, 02072
- Region
- Stoughton, MA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 17.8
- EV/EBITDA
- 3.1
- Price/Sales
- 1.5
- Price/Book
- 3.7
Growth
- Revenue
- +23.6%
- EPS
- -7.5%
- Free Cash Flow
- +61.1%
Profitability
- Gross Margin
- 59.3%
- Operating Margin
- 23.0%
- Net Margin
- 8.1%
- ROE
- 24.1%
- ROIC
- 9.8%
Balance Sheet
- Debt/Equity
- 3.12
- Current Ratio
- 1.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.